You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Attention Score in Context
| Title |
Changes in Cost and Insurance Challenges to Cover PrEP Between 2019 and 2021
|
|---|---|
| Published in |
JAIDS: Journal of Acquired Immune Deficiency Syndromes, June 2023
|
| DOI | 10.1097/qai.0000000000003180 |
| Pubmed ID | |
| Authors |
Alexa B. D'Angelo, Chloe Mirzayi, Pedro B. Carneiro, Christian Grov |
| Abstract |
PrEP use cotinues lag estimated need among gay and bisexual men in the U.S. Studies report that challenges paying for PrEP may undermine continued use. Our study aimed to measure these challenges over time. Data were taken from a U.S. national cohort study of cisgender gay and bisexual men and transgender individuals aged 16 to 49. We analyzed data from PrEP-using participants between 2019-2021 and observed cost- and insurance-related challenges participants experienced while on PrEP across timepoints. We report McNemar and Cochrane's Q test statistics to compare differences between groups by year(s). In 2019, 16.5% (n = 828/5013) of participants were on PrEP; by 2020, 21% (n = 995/4727) were on PrEP and by 2021, 24.5% (n = 1133/4617) were on PrEP. The proportion of those experiencing challenges paying for PrEP-care decreased significantly across timepoints for clinical appointments, lab work and prescriptions. Those experiencing insurance and copay approval issues did not change significantly. Though not statistically significant, the only proportion that increased over time was those reporting PrEP-related insurance approval issues. In a post-hoc analysis, we found that those reporting PrEP use in the past year who were not currently on PrEP, were significantly more likely to report experiencing most PrEP challenges, when compared to current PrEP users. We found significant reductions in insurance and cost-related challenges between 2019 and 2021. However, those who discontinued PrEP within the past year reported greater challenges paying for PrEP, suggesting that cost and insurance issues may undermine PrEP persistence. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 75% |
| Unknown | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 3 | 75% |
| Members of the public | 1 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 25. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2023.
All research outputs
#1,526,523
of 25,394,764 outputs
Outputs from JAIDS: Journal of Acquired Immune Deficiency Syndromes
#142
of 4,810 outputs
Outputs of similar age
#30,022
of 388,748 outputs
Outputs of similar age from JAIDS: Journal of Acquired Immune Deficiency Syndromes
#1
of 20 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,810 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,748 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.